CYTEIR THERAPEUTICS INC (CYT) Stock Price, Forecast & Analysis
USA - NASDAQ:CYT - US23284P1030 - Common Stock
CYT Key Statistics, Chart & Performance
The current stock price of CYT is 3.02 USD. In the past month the price decreased by -2.89%. In the past year, price increased by 81.93%.
CYT Latest News, Press Relases and Analysis
CYT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About CYT
Company Profile
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
Company Info
CYTEIR THERAPEUTICS INC
99 Hayden Avenue, Building B, Suite 450
Lexington MASSACHUSETTS US
CEO: Markus Renschler
Employees: 46
Phone: 18572854140
CYTEIR THERAPEUTICS INC / CYT FAQ
Can you describe the business of CYTEIR THERAPEUTICS INC?
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. The company is headquartered in Lexington, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2021-06-18. The firm is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. Its CYT-0851 is also in development in combination with capecitabine and gemcitabine in a Phase I/II clinical study, including patients with advanced ovarian cancer.
What is the current price of CYT stock?
The current stock price of CYT is 3.02 USD. The price decreased by -2.27% in the last trading session.
Does CYT stock pay dividends?
CYT does not pay a dividend.
How is the ChartMill rating for CYTEIR THERAPEUTICS INC?
CYT has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for CYTEIR THERAPEUTICS INC?
CYTEIR THERAPEUTICS INC (CYT) currently has 46 employees.
What is the market capitalization of CYT stock?
CYTEIR THERAPEUTICS INC (CYT) has a market capitalization of 108.72M USD. This makes CYT a Micro Cap stock.
CYT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CYT. When comparing the yearly performance of all stocks, CYT is one of the better performing stocks in the market, outperforming 90.36% of all stocks.
CYT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CYT. No worries on liquidiy or solvency for CYT as it has an excellent financial health rating, but there are worries on the profitability.
CYT Financial Highlights
Over the last trailing twelve months CYT reported a non-GAAP Earnings per Share(EPS) of -1.3. The EPS increased by 31.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.35% | ||
| ROE | -26.57% | ||
| Debt/Equity | 0 |
CYT Forecast & Estimates
8 analysts have analysed CYT and the average price target is 3.06 USD. This implies a price increase of 1.32% is expected in the next year compared to the current price of 3.02.